AGL INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of agilon health
newsfilecorp.com
Want to monitor EYPT?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor EYPTEYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasert® sustained release technology with vorolanib, a tyrosine kinase inhibitor. Vorolanib provided clear efficacy signals in two prior human trials in wet AMD as an orally delivered therapy with no significant ocular adverse events.